Skip to main content
Clinical Trials/NCT01108302
NCT01108302
Withdrawn
N/A

Assessing the Effectiveness, Safety and Feasibility of Expanding Use of Oxytocin in Uniject™ by Auxiliary Nurse Midwives to Prevent Postpartum Hemorrhage: A Community-based Cluster Randomized Trial in Bagalkot, India

Johns Hopkins Bloomberg School of Public Health1 site in 1 countrySeptember 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Postpartum Hemorrhage
Sponsor
Johns Hopkins Bloomberg School of Public Health
Locations
1
Primary Endpoint
postpartum hemorrhage
Status
Withdrawn
Last Updated
14 years ago

Overview

Brief Summary

This cluster randomized community-based trial is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by an Auxiliary Nurse Midwife (ANM) at births occurring in homes, Sub-Centers and Primary Health Centers in Bagalkot, India will reduce the risk of postpartum hemorrhage by 44% (from 9% to 5%) relative to home births attended by the same type of provider who does not provide the intervention drug. The study will also document correct use of oxytocin in Uniject, adverse maternal and fetal events associated with inappropriate use and a number of indicators reflecting the programmatic feasibility of implementing this intervention.

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
June 2013
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • gestational age \>=28 wks at enrollment
  • anticipate spontaneous vaginal delivery
  • hemoglobin \>=8 gm/dl
  • delivery at home, sub-center, or primary health center
  • delivery attended by Auxilliary Nurse Midwife

Exclusion Criteria

  • previous caesarean-section
  • scheduled for caesarean-section
  • antepartum bleeding during current pregnancy
  • blood pressure \>140mm of Hg systolic and \>90mm of Hg diastolic
  • in active labor at time of recruitment
  • high risk medical conditions (diabetes, cardiac ailments, seizures, placenta previa, anticipated breech delivery

Outcomes

Primary Outcomes

postpartum hemorrhage

Time Frame: after delivery of baby

blood loss \>=500 ml after delivery of the baby, as measured through a plastic calibrated drape.

Secondary Outcomes

  • Oxytocin use before delivery(labor and delivery)
  • stillbirth(pregnancy)
  • neonatal death(first month of life)
  • need for neonatal resuscitation(0-6 hours after birth)

Study Sites (1)

Loading locations...

Similar Trials